Autoimmune Hair Loss Treatment at The Birmingham Hair Revive Clinic
Waking up to find patches of hair missing from your scalp can be alarming. When your own immune system turns against your hair follicles, it creates a unique challenge that extends far beyond cosmetic concerns. Autoimmune hair loss affects thousands of people across the West Midlands, yet many don’t understand why it happens or what can be done about it.
Understanding Autoimmune Hair Loss
Your immune system exists to protect you, identifying and neutralising threats like viruses and bacteria. In autoimmune conditions, this sophisticated defence system malfunctions, mistaking your body’s own healthy tissues for foreign invaders. When this happens to hair follicles, the result is autoimmune hair loss.
Unlike genetic pattern baldness or hair loss from nutritional deficiencies, autoimmune hair loss stems from your body attacking itself. The condition can manifest in various forms, from small circular patches to complete scalp hair loss, and sometimes extends to eyebrows, eyelashes, and body hair.
The Most Common Form: Alopecia Areata
Alopecia areata represents the most prevalent autoimmune hair loss condition in the UK. According to medical data, it affects approximately 1 in every 170 adults, which translates to around 300,000 people across Britain. The condition shows no preference for age or gender, though it typically first appears during childhood or early adulthood.
How Alopecia Areata Develops
In alopecia areata, T-cells (a type of white blood cell) mistakenly identify hair follicles as threats. These immune cells surround and attack the follicles, disrupting the normal hair growth cycle. The follicles shift prematurely from the active growth phase into the resting phase, causing hair to fall out in distinctive round or oval patches.
The characteristic appearance involves smooth, round bald spots on the scalp, usually lacking any itching, scaling, or redness. The affected skin remains healthy, and the hair follicles themselves survive. This distinguishes alopecia areata from scarring alopecias where follicles are permanently destroyed.
Different Forms of the Condition
The British Association of Dermatologists recognises several variants:
Alopecia Areata (Patchy): The most common form, presenting as one or more coin-sized bald patches on the scalp. These patches may merge together but leave the follicles intact.
Alopecia Totalis: Complete loss of all scalp hair. This represents a more severe progression where the autoimmune response targets follicles across the entire scalp.
Alopecia Universalis: The rarest and most extensive form, causing complete hair loss across the scalp, face, and entire body. This affects eyebrows, eyelashes, beard areas, and body hair.
Ophiasis: A distinctive pattern where hair loss occurs in a band shape around the sides and back of the scalp, almost the reverse pattern of androgenetic alopecia.
The Unpredictable Nature of Alopecia Areata
One of the most challenging aspects of alopecia areata is its unpredictability. According to data from UK dermatology services, over 50% of people with patchy disease lasting less than a year will experience spontaneous remission. Hair simply begins growing back without intervention.
However, this recovery doesn’t guarantee permanent resolution. Many individuals experience recurring episodes throughout their lives, with 86-100% of patients developing further episodes at some point. Approximately 30% of people with patchy disease eventually progress to more extensive hair loss.
Certain factors indicate more challenging cases. If alopecia areata begins before puberty, affects more than 50% of the scalp, follows the ophiasis pattern, or is accompanied by nail changes, the prognosis tends to be less favourable with lower remission rates and poorer treatment responses.
Other Autoimmune Conditions Causing Hair Loss
While alopecia areata specifically targets hair follicles, several systemic autoimmune diseases affect hair as part of their broader impact on the body.
Lupus-Related Hair Loss
Systemic lupus erythematosus (SLE) causes hair loss in up to 85% of patients. This autoimmune condition attacks multiple organ systems, and hair loss often serves as an early warning sign. The inflammation characteristic of lupus affects hair follicles in several ways, creating different patterns of loss.
Diffuse non-scarring hair loss with SLE resembles telogen effluvium, with general thinning across the scalp occurring during disease flares. Unlike simple telogen effluvium, which develops months after a stressful event, lupus-related shedding happens concurrently with active disease.
“Lupus hair” describes the characteristic brittle, broken hairs along the frontal hairline, giving a distinctive dry, coarse appearance. These fragile strands break easily, creating a receding appearance that differs from genetic baldness.
Discoid lupus erythematosus (DLE) represents the scarring form of lupus-related hair loss. Disc-shaped lesions develop on the scalp, causing inflammation that permanently damages follicles. Early treatment is crucial because once scarring occurs, those follicles cannot regenerate.
Thyroid-Related Autoimmune Hair Loss
Hashimoto’s thyroiditis and Graves’ disease are autoimmune thyroid conditions that frequently cause hair loss. Interestingly, people with alopecia areata show higher rates of thyroid dysfunction, with approximately 9% having some form of thyroid disorder. The connection suggests a shared autoimmune susceptibility.
Rheumatoid Arthritis and Hair Loss
Research from large UK cohorts shows that rheumatoid arthritis patients experience hair loss at twice the rate of the general population. The chronic inflammation characteristic of RA can trigger telogen effluvium, while some individuals develop concurrent alopecia areata.
NHS Treatment Options
The NHS recognises alopecia areata as a treatable condition, though options vary depending on severity and location. Your GP serves as the first point of contact, and certain treatments are available through NHS prescription.
Contact Immunotherapy
For extensive alopecia areata, the NHS considers contact immunotherapy (such as diphencyprone or DPC) the most effective treatment. This approach deliberately creates an allergic reaction on the scalp to redirect the autoimmune attack away from hair follicles.
The treatment involves first sensitising your skin to the chemical, then applying it regularly to affected areas. This creates a controlled inflammatory response that somehow “distracts” the immune system from attacking hair follicles. While it sounds counterintuitive, clinical evidence supports its effectiveness for extensive disease.
Corticosteroid Treatments
For localised patchy alopecia areata, corticosteroid injections directly into or near the bald patches represent the first-line treatment. These injections suppress local immune activity, giving follicles a chance to resume normal function. Treatments are typically repeated every 4-6 weeks.
Topical corticosteroid creams offer a less invasive option for mild cases, though they generally prove less effective than injections. The British Association of Dermatologists notes that response rates vary considerably between individuals.
Ritlecitinib: A Breakthrough NHS Treatment
In February 2024, NICE recommended ritlecitinib (Litfulo) for severe alopecia areata, marking a historic moment as the first medicine for this condition approved for routine NHS commissioning. The medication works by blocking JAK enzymes that contribute to the autoimmune response.
Clinical trials showed impressive results. After 24 weeks of treatment, 13% of patients achieved 90% or more scalp coverage, compared to just 1.5% of those receiving placebo. Almost half of participants reported moderate to great improvement in their hair loss.
To qualify for ritlecitinib through the NHS, patients must have severe alopecia areata affecting at least 50% of their scalp (measured using the SALT score). The medication is available for people aged 12 and over, taken as a daily pill at home.
Alopecia UK, the leading charity supporting people with the condition, describes this approval as “a monumental day for the alopecia areata community,” noting that effective licensed treatments have been long overdue.
Challenges in NHS Access
Despite these treatment options, many Birmingham residents encounter obstacles accessing specialist care. As Alopecia UK’s chief executive Sue Schilling points out, “Our community still faces substantial barriers including difficulties in getting a dermatology referral from their GP, unacceptable dermatology waiting times, and even some NHS trusts making the decision not to allow dermatology appointments for alopecia patients.”
Some NHS regions have limited dermatology capacity for alopecia areata, with waiting times extending many months. Additionally, not all treatments suit every patient, and responses vary significantly between individuals.
